Friday, 12 August 2011
Daclizumab demonstrates significant reduction in relapse rate
Source: The MS Trust:
Daclizumab, a monoclonal antibody, has been found to significantly reduce annualized relapse rates in people with relapsing remitting MS in the SELECT trial.
Read article here.